Trial Profile
Multicenter, prospective interventional study to evaluate therapeutic effect of Afatinib in patients with advanced non-small cell lung cancer, EGFR mutation positive and brain metastasis.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.
- 05 Feb 2018 New trial record